The nano-revolution reaches the heart: the EU-funded project CUPIDO

Cardiovascular diseases, such as myocardial infarct and heart failure, represent a societal burden, accounting for more than 30% of deaths globally and spending yearly ~190 billion € in European healthcare. The chronic treatment of patients leads only to short-term benefits, since the conventional therapies show several weak points.

The available drug-delivery methods, oral and intravenous, allow the drug to circulate systematically in the blood stream causing several side-effects and loosing efficacy. During the end-stages of the disease, the administration might become even more invasive, employing catheters or implantable pumps.

This highlights the urgent need to develop new patient-friendly therapeutic strategies that are more efficient, safe and heart-specific.

PlumeStars, startup company founded in September 2013, is one of the partners that participates and gives important contribute to the EU-funded project Cupido, started in February 2017.

Cupido aims to hit the core of the cardiovascular disease, developing inhalable nanoparticles that can deliver, as simple as breathing, a therapeutic directly to the diseased heart. Nanoparticles are extremely tiny, almost 1 million times smaller in size than a grain of sand and far too small to see with conventional microscopes. Exploiting such a tiny system as a route of administration can revolutionize the cardiovascular field, becoming the first non-invasive and heart-specific therapeutic approach.

To achieve the goal, the Cupido consortium is working to develop biocompatible and biodegradable nanoparticles that can self-assemble and encapsulate drugs (novel or available) in a suitable form for the treatment of cardiovascular disease. The nanoparticles, once inhaled, will translocate through the lungs and fast reach the heart, where the drug will be finally released on the site of interest. The heart-specificity will be ensured thanks to chemical and/or magnetic guidance, reducing the chances of adverse side effects and lowering the required amounts of therapeutic compound.

The role of PlumeStars within the Cupid project is to develop the inhaled formulation, that is, to build microparticles carrying the drug encapsulated in nanoparticles.

The EU-based consortium, composed of 6 academic research groups, 5 SMEs, 2 industries, and 1 pharmaceutical company, gathers a vast array of expertise and joins cutting-edge research with pre-clinical experience and industrial manufacturing. The 4-year project, funded with 6M € under the EU Horizon 2020 Framework Program, aims to proof the preclinical feasibility of the nanotherapy, preparing the way for future clinical trials.



CNR – National Research Council of Italy

Charité – Universitätsmedizin Berlin

Simula Research Laboratory AS

Imperial College of Science, Technology and Medicine

BET solution

IN S.r.l

Cambridge Innovation Technologies Consulting Ltd

Sanofi-Aventis Recherche & Developpement


L.I.F.E. Corporation S.A.

PlumeStars S.r.l.

Find CUPIDO on the web at

Download Poster Cupido Project

Signed the Framework Agreement between the University of Parma and PlumeStars s.r.l.

On Friday, July 21, 2017, a Framework Agreement has been signed between the University of Parma and PlumeStars s.r.l. concerning a didactic and scientific collaboration between the Food and Drug Department and the start up PlumeStars.

The purpose of the convention is to cooperate for the development of innovative medicines with particular reference to the systemic inhalation product object of EUproject CUPIDO.

The collaboration will also focus on the development of orphan medicines, high-level training activities on innovative products and dissemination of knowledge through scientific publications, Meetings and Conference attendance.

The Framework Agreement also involves the Departments, Study Courses, University Organizational Units, as well as of Italian and international students and trainees in the various research lines that will emerge during the collaboration.

Plumestars aims to achieve important results in terms of novel drug product development to ensure a robust image of innovation capability, both in the inhalers and in the medicines for orphan diseases .

Plumestars’ participation at R2B – Research to Business 2017 at Bologna Fiere

On June 8th, the 11th edition of the Innovation & Match 2017 was held, the intermediation event with bilateral meetings between companies, research centers and universities, organized by ASTER and Emilia-Romagna Enterprise Europe Network partners of the SIMPLER consortium.

The event took place within R2B – Research to Business 2017, the 12th edition of the International Industrial Research Exhibition, promoted by the Emilia-Romagna Region, Bologna Fiere, ASTER and SMAU.

R2B 2017 aims to foster new business opportunities between research and business systems since 2005.

PlumeStars actively participated in the event, meeting potential customers and presenting the following products:

  1. A breathable antibacterial amikacin powder for pulmonary infections in cystic fibrosis. Innovation in this product has been achieved by building a powder of amikacin with high drug content to be administered with a dry powder inhaler.
  2. A film of hyaluronic acid loaded with cisplatin to be implanted in the operative site immediately after surgery of pleural mesothelioma. The film covers the pleural cavity where it slowly releases the drug to locally maintain its cytostatic effect for a long time, at the site where recurrences occur frequently.
  3. A thalidomide powder preparation to be used in oral / nasal therapy of hereditary hemorrhagic telangiectasia, a disease that causes frequent and abundant bleeding from the nose. PlumeStars has proposed to prolong the beneficial effect demonstrated in human by thalidomide oral treatment, administering the drug directly to the nasal cavity.




PlumeStars attended the 57th AFI Symposium

PlumeStars actively participated at the 57th AFI Symposium, the Italian Conference of the Industrial Pharmacists, held on 7-8 and 9 June at the Pala Congressi in Rimini. The symposium has registered more than 1000 attendees and more than 100 stands, reconfirming itself as a meeting point for excellence which revolves around the pharmaceutical world.

The 57th AFI Symposium organized the “Startup Square”, an area specifically dedicated within the exhibition space and accessible for free to allow visitors and companies to come in direct contact with the innovative realities present.

PlumeStars presented in a speech of Prof. Paolo Colombo (PlumeStars CEO) The Orphan Medicine Initiative, describing important achievements in the field of orphan medicines. The novel orphan medicines presented in Rimini were:

  • Amikacin & tobramycin powders for inhalations in cystic fibrosis
  • Cisplatin films for local delivery in mesothelioma recurrences
  • Thalidomide powder for oral and nasal delivery in Hereditary Haemorrhagic Telangiectasia.


Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.